Crypto trader and stock investor Lark Davis says he’s tracking five low-cost altcoins on Binance right now, including two he believes will achieve unicorn status.
Although it’s priced at just $0.33, the first alt coin on his list, Polygon, has a high market cap at $1.8 billion.
“In spite of the high market cap, I currently believe this is a coin with some serious potential that the wider market really seems to not understand at this time.”
Davis says Polygon has an ecosystem that is bigger than many other block chains with bigger market caps, and cites several upcoming integrations as reasons why he thinks Polygon’s value will increase.
Next on his list is Injective Protocol (INJ), which Davis labels as “a beast.” Still in its test net phase, Injective offers zero gas-fee trades due to Layer Two technology.
Injective also offers derivatives trading, including futures contracts. He expects Injective to achieve unicorn status ($1 billion market cap) when its main net launches.
Davis is also bullish on Marlin (POND). The high-performance layer zero block chain network is geared toward delivering high-quality infrastructure for decentralized finance (DeFi).
“Think of it like a high-octane gas that they can use to make things go better.”
Number four on the list is Kava, which is an underrated but powerful DeFi protocol, according to Davis.
Kava allows traders to lend, borrow, earn and exchange on its platform for low-priced fees. It’s also bringing a new suite of products to the market.
Davis, who’s been bullish on Kava for a long time, believes it will be a billon dollar market cap crypto asset.
Last on the list is Open Ocean (OOE). It’s still in the token sale phase, but it makes Davis’ top five list because Binance is a lead investor.
“Binance almost always lists the coins that they invest in.”
Open Ocean is an aggregator working across centralized exchange services to find the best prices and lowest slippage possible on the market.
I
Don't Miss a Beat – Subscribe to get email alerts delivered directly to your inboxFeatured Image: Shutterstock/Bioraven